Revance Therapeutics (RVNC) EBITDA (2014 - 2024)
Revance Therapeutics (RVNC) EBITDA from Mar 31, 2014 to Sep 30, 2024. The TTM Revance Therapeutics (RVNC) EBITDA is -$191M. You can adjust inflation or export chart.
Annual EBITDA
Quarterly EBITDA
Revance Therapeutics (RVNC) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +3.20% |
| 3 Years TTM | -11.22% |
| 5 Years TTM | +4.34% |
| 10 Years TTM | +17.92% |
| All Time TTM | +14.16% |
Annual EBITDA change of Revance Therapeutics (RVNC)
| Year | EBITDA | Change |
|---|---|---|
| 2024 | -$109M | -48.10% |
| 2023 | -$210M | -9.92% |
| 2022 | -$233M | -8.56% |
| 2021 | -$255M | -3.08% |
| 2020 | -$263M | +62.74% |
| 2019 | -$162M | +14.65% |
| 2018 | -$141M | +21.44% |
| 2017 | -$116M | +49.31% |
| 2016 | -$78M | +10.51% |
| 2015 | -$70M | +35.10% |
| 2014 | -$52M | N/A |